1. Scrip
  2. >>R&D
  3. >>Clinical Trials

An ASH That Moves The Ball – And The Ticker Price

 
• By Jessica Merrill

The American Society of Hematology meeting showcased breakthroughs and some ho-hum news, resulting in rollercoaster-like crests and troughs for biotech stocks.

Hitting bigger business target

In a year of notable advances in blood cancer and gene therapy, the American Society of Hematology (ASH) annual meeting Dec. 9-12 presented the opportunity for drug companies to showcase their latest advances. Big news on potentially paradigm-changing medicines were rewarded as investors clung on for a soaring ride, while Wall Street's reaction to less-than-stellar news coming out of ASH was about as blustery as the December snowstorm that hit Atlanta on the opening day.

Biotech stocks relying on the success of one or two late-stage products experienced big stock fluctuations on Monday morning after...

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.